Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Osanetant - Acer Therapeutics

Drug Profile

Osanetant - Acer Therapeutics

Alternative Names: SR 142801; SR 142806

Latest Information Update: 11 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antidepressants; Antipsychotics; Anxiolytics; Piperidines
  • Mechanism of Action Neurokinin 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anxiety disorders; Major depressive disorder; Schizophrenia

Most Recent Events

  • 13 Aug 2019 Acer Therapeutics plans to submit IND application to the US FDA for Neuroendocrine-related disorders in Q2 2020
  • 13 Aug 2019 Acer Therapeutics plans a phase I/II trial for Neuroendocrine-related disorders (in patients patients with induced vasomotor symptoms (iVMS) in second half of 2020
  • 02 Jan 2019 Osanetant licensed to Acer Therapeutics worldwide for Neuroendocrine diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top